AskAt received a notice of allowance dated April 20, 2021 of a use patent for its EP4 receptor antagonist in the treatment of cartilage disease. The notice was issued by the Canadian Intellectual Property Office (CIPO), in connection with Canadian Patent Application No. 2,907,049 (Filing Date: March 19, 2014). In addition to Canada, the use patent has been granted in Japan, Mexico, Russia, and the United States.